Phase II Study of the Efficacy of the EGFR Inhibitor Mefatinib in Patients with Advanced EGFR-mutant NSCLC

被引：0
|
作者：
Wang, P. [1 ]
Li, Y. [2 ]
Lv, D. [3 ]
Ding, L. [1 ]
Hong, W. [4 ]
Han-Zhang, H. [5 ]
Lin, J. [5 ]
Zhou, J. [6 ]
Wang, K. [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Resp Med, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Affiliated Hosp 1, Dept Pulm & Crit Care Med, Wenzhou, Peoples R China
[3] Wenzhou Med Univ, Taizhou Hosp, Dept Resp Med, Taizhou, Peoples R China
[4] Zhejiang Canc Hosp, Dept Med Oncol, Hangzhou, Peoples R China
[5] Burning Rock Biotechnol Co Ltd, Guangzhou, Peoples R China
[6] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Resp Dis,Thorac Dis Ctr, Hangzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
EGFR Inhibitor; Mefatinib; advanced NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.28
引用
收藏
页码：S598 / S599
页数：2
相关论文
共 50 条
  • [1] Efficacy and Safety of Aumolertinib with Radiotherapy in the Treatment of Unresectable Locally Advanced EGFR-Mutant NSCLC: A Phase II Study
    Meng, X.
    Kong, L.
    Zhao, K.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S581 - S581
  • [2] A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC
    Lisberg, A.
    Cummings, A.
    Goldman, J. W.
    Bornazyan, K.
    Reese, N.
    Wang, T.
    Coluzzi, P.
    Ledezma, B.
    Mendenhall, M.
    Hunt, J.
    Wolf, B.
    Jones, B.
    Madrigal, J.
    Horton, J.
    Spiegel, M.
    Carroll, J.
    Gukasyan, J.
    Williams, T.
    Sauer, L.
    Wells, C.
    Hardy, A.
    Linares, P.
    Lim, C.
    Ma, L.
    Adame, C.
    Garon, Edward B.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (08) : 1138 - 1145
  • [3] Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations
    Li, Xuefei
    Cai, Weijing
    Yang, Guohua
    Su, Chunxia
    Ren, Shengxiang
    Zhao, Chao
    Hu, Rongjun
    Chen, Xiaoxia
    Gao, Guanghui
    Guo, Zhiwei
    Li, Wei
    Zhou, Caicun
    Hirsch, Fred R.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (09) : 1388 - 1397
  • [4] Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC
    Gettinger, Scott
    Hellmann, Matthew D.
    Chow, Laura Q. M.
    Borghaei, Hossein
    Antonia, Scott
    Brahmer, Julie R.
    Goldman, Jonathan W.
    Gerber, David E.
    Juergens, Rosalyn A.
    Shepherd, Frances A.
    Laurie, Scott A.
    Young, Tina C.
    Li, Xuemei
    Geese, William J.
    Rizvi, Naiyer
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1363 - 1372
  • [5] Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters
    Estevinho, F.
    Felizardo, M.
    Fernandes, G.
    Figueiredo, A.
    Lopes, A.
    PULMONOLOGY, 2019, 25 (05): : 306 - 309
  • [6] Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study
    Wang, Pingli
    Li, Yuping
    Lv, Dongqing
    Yang, Lingge
    Ding, Liren
    Zhou, Jianya
    Hong, Wei
    Chen, Youfei
    Zhang, Dongqing
    He, Susu
    Zhou, Jianying
    Wang, Kai
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [7] Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study
    Pingli Wang
    Yuping Li
    Dongqing Lv
    Lingge Yang
    Liren Ding
    Jianya Zhou
    Wei Hong
    Youfei Chen
    Dongqing Zhang
    Susu He
    Jianying Zhou
    Kai Wang
    Signal Transduction and Targeted Therapy, 6
  • [8] EGFR Mutation Testing Using Liquid Biopsy Technology for Patients with Advanced EGFR-Mutant NSCLC
    Seitz, Jan
    Moskalev, Evgeny A.
    Fuchs, Florian
    Haller, Florian
    Hartmann, Arndt
    MODERN PATHOLOGY, 2018, 31 : 750 - 750
  • [9] EGFR Mutation Testing Using Liquid Biopsy Technology for Patients with Advanced EGFR-Mutant NSCLC
    Seitz, Jan
    Moskalev, Evgeny A.
    Fuchs, Florian
    Haller, Florian
    Hartmann, Arndt
    LABORATORY INVESTIGATION, 2018, 98 : 750 - 750
  • [10] First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC
    Ricciuti, Biagio
    Chiari, Rita
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S127 - S130
12345